Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 26, 2000

View Archived Issues

Inhibition of NK cells by cancer cells from patients with CML prevented by Maxamine

SangStat's Thymoglobulin granted orphan drug designation in U.S.

The hypothalamo-hypophyseal-adrenal axis influences arthritis development, treatment

Lisinopril found to regress myocardial fibrosis in hypertensive patients

Consensus on Statins -- International Task Force Webcast now available on demand

Vernalis's clinical development programs continue to make good progress

ImmunoGen/SmithKline Beecham open second trial of cancer treatment

Antidepressants with novel mechanism of action identified at SB

AstraZeneca presents new DOP-selective analgesic candidate in Bologna

MBR ligands under development at Dainippon as safe and effective anxiolytic agents

SRI reports synthesis and activity of new anti-MAC compounds targeting DHFR

Novel anti-MRSA cephalosporin and prodrug emerge from Microcide/R.W. Johnson collaboration

Coulter acquires rights to anticancer compounds

Broad-spectrum antiherpesvirus agents from Pharmacia target viral polymerase

Zefix approved in Japan for chronic HBV infection

Japanese approval granted for Diovan, a new antihypertensive agent

Merck discusses preparation and methods of using integrin antagonists for bone disorders, etc.

Synthesis and use of quinazoline-based VEGF receptor tyrosine kinase inhibitors

Research program at SB on orexin receptor antagonists yields results

Roche discloses novel MMP inhibitors particularly useful in the control of cancer

Lactam factor Xa inhibitors designed by BMS research groups

Protein farnesyltransferase inhibitors and their use in cancer treatment described by Pfizer

Merck patents new series of tachykinin NK1 receptor antagonists

Aptosyn NDA for FAP indication not approvable at this time

FDA denies approval of Foscan

Promising antischizophrenia agent shows safety and efficacy in phase III

Vical reports interim data from phase II trial of Leuvectin

Corixa and Purdue establish agreement for therapeutic antibodies for cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...